Napoli Shkolnik filed a lawsuit on August 7 on behalf of a Maryland couple against the makers of Dupixent, alleging that the widely prescribed eczema drug caused a rare and generally incurable cancer and that the companies knew about the risk for years without adding it to the drug’s U.S. warning label.
The firm filed in the same New Jersey federal court where Dupixent cancer claims from across the country are being consolidated.
What the lawsuit alleges
Taj Sheppard sought treatment for eczema in June 2019 and was prescribed a course of Dupixent injections. According to the complaint, in October 2019, four months after he started the drug, doctors diagnosed him with cutaneous T-cell lymphoma (CTCL), a rare cancer that begins in the skin and is generally considered incurable.
Napoli Shkolnik filed on behalf of Sheppard and his wife in the U.S. District Court for the District of New Jersey in Trenton, naming Sanofi-Aventis U.S. and Regeneron Pharmaceuticals as defendants.
The complaint points to evidence that the manufacturers knew of this risk for years. In March 2025, the FDA publicly identified Dupixent as having a potential signal of serious risk of CTCL and said it was evaluating the need for regulatory action. As of the August filing, the complaint alleges that no labeling revision had been made.
The lawsuit further alleges that the companies told physicians Dupixent required no initial laboratory testing and no ongoing laboratory monitoring, during a period when researchers were recommending biopsies before and during treatment.
Partner Shayna E. Sacks, who represents the Sheppards, told Law.com:
“Taj Sheppard was prescribed a drug for his eczema and was diagnosed with cancer four months later. The research linking Dupixent to that cancer had been building since 2018, and the FDA flagged the risk publicly last year, but no warning was ever added to the label. We are bringing this case to hold Regeneron and Sanofi accountable for that failure, and to put this risk in front of the patients and physicians who are still relying on that label today.”
Who may have a claim
If you or someone you love has been diagnosed with CTCL after using Dupixent, you do not have to navigate this situation alone.
Our experienced product liability attorneys are actively investigating potential claims related to Dupixent and cancer risk. We can help determine whether you may be eligible to pursue compensation.
Contact us today for a free, no-obligation consultation. There are no upfront costs, and you pay nothing unless we recover compensation on your behalf.